(Q51747146)
Statements
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease (English)
Anatole Besarab
Moro O Salifu
N Martin Lunde
Vinod Bansal
Steven Fishbane
Frank C Dougherty
Ba16285 Study Investigators